NCT02332668View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

March 18, 2015

Primary Completion Date

October 25, 2027

Study Completion Date

October 25, 2027

Conditions
MelanomaLymphomaSolid TumorClassical Hodgkin LymphomaMicrosatellite-instability-high Solid Tumor
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

Trial Locations (17)

4130

RECRUITING

MSD Korea LTD, Seoul

10032

RECRUITING

Call for Information (Investigational Site 0031), New York

45229

RECRUITING

Call for Information (Investigational Site 0032), Cincinnati

57117

RECRUITING

Call for Information (Investigational Site 0071), Sioux Falls

58122

RECRUITING

Call for Information (Investigational Site 0070), Fargo

75235

RECRUITING

Call for Information (Investigational Site 0054), Dallas

80045

RECRUITING

Call for Information (Investigational Site 0019), Aurora

02445

RECRUITING

Call for Information (Investigational Site 0026), Boston

Unknown

RECRUITING

MSD Brasil, São Paulo

RECRUITING

MSD France, Paris

RECRUITING

MSD Sharp & Dohme GmbH, München

RECRUITING

Merck Sharp & Dohme Co. Ltd., Hod HaSharon

RECRUITING

MSD Italia S.r.l., Rome

RECRUITING

Merck Sharp & Dohme BV, Haarlem

RECRUITING

Merck Sharp & Dohme Lda., Paço de Arcos

RECRUITING

MSD Sweden, Stockholm

RECRUITING

Merck Sharp & Dohme Ltd., London

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY